오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: purified water; povidone; potato starch; ethanol; docusate sodium; magnesium stearate; lactose monohydrate; colloidal anhydrous silica - for temporary relief of acute moderate pain.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: stearic acid; sodium lauryl sulfate; maize starch; colloidal anhydrous silica; pregelatinised maize starch; purified talc; hyprolose; magnesium stearate; povidone - for the temporary relief of acute moderate pain

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; magnesium stearate; povidone; colloidal anhydrous silica; sodium lauryl sulfate; sodium starch glycollate - temporary relief of acute moderate pain and fever.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet - excipient ingredients: magnesium stearate; povidone; pregelatinised maize starch; stearic acid - gppl paracetamol codeine 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - paracetamol; codeine phosphate hemihydrate; caffeine - effervescent tablet - 500/8/30 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 8 mg - tablet, uncoated - excipient ingredients: erythrosine aluminium lake; lactose monohydrate; magnesium stearate; potato starch; povidone; docusate sodium; colloidal anhydrous silica - for the temporary relief of acute moderate pain in patients over the age of 12 years

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - codeine phosphate hemihydrate 15mg;   - tablet - 15 mg - active: codeine phosphate hemihydrate 15mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water   sodium starch glycolate

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - codeine phosphate hemihydrate 30mg;   - tablet - 30 mg - active: codeine phosphate hemihydrate 30mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water   sodium starch glycolate

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - codeine phosphate hemihydrate 60mg;   - tablet - 60 mg - active: codeine phosphate hemihydrate 60mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b povidone purified water   sodium starch glycolate

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 450 mg; codeine phosphate hemihydrate, quantity: 30 mg; doxylamine succinate, quantity: 5 mg - tablet, uncoated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; sodium starch glycollate; hypromellose - mevadol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.